Rheumatology News and Research

RSS

Rheumatology is a sub-specialty in internal medicine and pediatrics, devoted to the diagnosis and therapy of rheumatic diseases. Rheumatologists mainly deal with clinical problems involving joints, soft tissues and allied conditions of connective tissues.

Minority women are disproportionately impacted by the autoimmune disease lupus

There is an urgent need for more education and research to address the fact that minority women are disproportionately impacted by the autoimmune disease lupus

14 May 2004

Thomson launches new online medical education portal

The Thomson Corporation, a provider of scientific and healthcare information solutions, announced today that it has developed a new online medical education portal.

5 May 2004

A new study is better defining the impact that stress and depression have on women suffering from rheumatoid arthritis

A new study is better defining the impact that stress and depression have on women suffering from rheumatoid arthritis (RA). The research, led by a team of ASU psychologists, shows increased pain and inflammation for those dealing with high amounts of stress and depression.

26 Apr 2004

Gout and alcohol link is verified

The association between alcohol consumption and risk of gout has been suspected since ancient times, but has not been prospectively confirmed. Additionally, potential differences in risk of gout posed by different alcoholic beverages have not been assessed.

17 Apr 2004

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

6 Apr 2004

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

Genentech, Inc. and XOMA Ltd. today announced preliminary results of a randomized, placebo-controlled Phase II study with RAPTIVA™ (efalizumab) in 107 patients with psoriatic arthritis. The study did not reach statistical significance at 12 weeks (84 days) for the primary endpoint, ACR 20 response. An ACR 20 response indicates at least a 20 percent improvement in an individual's signs and symptoms of arthritis.

22 Mar 2004